When is ABEO's next earnings date?

Based on SEC filing cadence, Abeona Therapeutics Inc. (ABEO)'s next quarterly reporting window is estimated around Dec 30, 2026.

How much is ABEO stock expected to move on earnings?

Volatility modeling currently projects a ±9.5% event move for ABEO, spanning a range between $3.85 and $4.65.

Stock Ratings / Health Care / ABEO / earnings

CAMP (26) AMRN (32) IFRX (54) EVMN (31) ⌘ Pro Terminal →

Abeona Therapeutics Inc. (ABEO) Next Earnings Date & Expected ±9.5% Move

Q: Where is ABEO trading relative to its 50-day, 200-day, and 52-week technical levels?

ABEO last traded at $4.25 (-2.30% on volume of 1,011,847 shares), positioning the stock -17.95% below its 50-day simple moving average ($5.18) and -22.45% below its 200-day simple moving average ($5.48). Across its 52-week range of $4.00 to $7.65, ABEO sits at the 6.8% percentile with a 14-day RSI of 38.7 (NEUTRAL RANGE) and an implied next-earnings move of ±9.5% ($3.85 to $4.65).

$4.25 -2.30% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $4.22

Abeona Therapeutics Inc. (ABEO) carries a Roarable Rating of E (Strong Sell) with 23/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (23/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $248.8M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ABEO Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ABEO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Abeona Therapeutics Inc. (NASDAQ: ABEO) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 23/100 at a spot price of $4.25 (-2.30% 1D, market cap $248.8M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ABEO ranks #947 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ABEO compare to CAMP and AMRN in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ABEO carries a Roarable E (23/100 RQD), trailing P/E of N/A, gross margin of 73.7%, and ROIC of -35.0%. By comparison, CAMP (CAMP4 Therapeutics Corporation) holds a E grade (26/100 RQD, P/E N/A, ROIC -35.0%, cap $248.5M) and AMRN (Amarin Corporation plc) posts a E grade (32/100 RQD, P/E N/A, ROIC -12.2%, cap $249.9M). Among the 5-stock peer group, ABEO leads on earnings multiple (N/A) while AMRN leads on capital efficiency (-12.2% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ABEO?

▼

Per ABEO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000318306), Abeona Therapeutics Inc. generated $5.8M in revenue (-96.8% YoY), -$71.2M in net income, and -$84.3M in free cash flow against $219.6M in total assets and $7.8M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $4.22 (-0.60%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (23/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-11.1% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E

Each axis scored 0–20

12M PRICE TARGET CONE-15.8% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ABEO)Realized 20D OHLCV Swing Band: ±9.5%

Deterministic 5-Pillar Attribution (23/100 Composite)

🔍 WHY ABEO SCORES 23/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+8/20 pts (35% of score)

FRED Regime × Technicals: 7% of 52W Range • RSI-14 at 38.7 (NEUTRAL RANGE)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+5/20 pts (22% of score)

Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) • Piotroski F-Score 3/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$4.52+1.8% Next Q

Q2 (-2Q)

Grade E$4.60-3.3% Next Q

Q3 (-1Q)

Grade E$4.45-4.5% Next Q

Current

Grade E$4.25-11.1% Hist 90D α

Trajectory: E (31) → E (23)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ABEO Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ABEO currently carries a cautious 23/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($5.18) and Max Pain ($4.46) forces dealer call-delta covering toward $8.03.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ABEO• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ABEO Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 23%NO 77%Trade / Inspect Odds →

NEXT EST. WINDOW: Dec 30, 2026 (~57 DAYS)

Historical OHLCV Volatility ±9.5% Swing Band

±$0.40 Expected Swing

MODEL EARNINGS SETUP GAUGE

ABEO Quantitative Pre-Earnings Setup: 23/100

Trailing EPS: $4.25 • YoY Revenue Growth: 12.4%

Model Bullish Setup (23/100)Model Risk Weight (77/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-12-31	$5.8M	-$71.2M	-$84.3M	73.7%
FY 2024	2024-12-31	$179.8M	$63.7M	-$58.5M	73.7%
FY 2023	2023-12-31	$3.5M	$54.2M	-$37.0M	73.7%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ABEO)

✓Walkthrough of ABEO's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ABEO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -28.57%📐 HORIZONTAL RANGE

2026-11-03O $4.56H $4.56L $4.25C $4.25VOL 783.4K

RES: $9.06SUP: $3.89SMA50: $5.18SMA200: $5.48

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ABEO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ABEO Butterfly Map → + Track ABEO →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ABEO today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ABEO. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ABEO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ABEO)

Health Care Rank #947 of 1016 ⚔️ CAMP vs ABEO Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ABEO vs. CAMP, AMRN, IFRX, EVMN)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Abeona Therapeutics Inc. (ABEO) ranks #947 by composite RQD confidence (23/100, grade E) and #543 by equity capitalization ($248.8M). Within this direct 5-issuer industry benchmark cohort, ABEO leads on earnings valuation at N/A trailing P/E, while AMRN leads on capital efficiency and profitability with -12.2% ROIC and 56.6% gross margin. IFRX currently holds the highest overall quantitative score in the immediate peer group at 54/100 (D+) compared with ABEO at 23/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ABEO ACTIVE Abeona Therapeutics Inc.	E	23/100	—	73.7%	-35.0%	-2.30%	$248.8M	Benchmark Subject
CAMP CAMP4 Therapeutics Corporation	E	26/100	—	—	-35.0%	-4.67%	$248.5M	/camp-vs-abeo →
AMRN Amarin Corporation plc	E	32/100	—	56.6%	-12.2%	+0.17%	$249.9M	/amrn-vs-abeo →
IFRX InflaRx N.V.	D+	54/100	—	—	—	+6.33%	$244.6M	/ifrx-vs-abeo →
EVMN Evommune Inc.	E	31/100	—	—	-35.0%	-10.70%	$244.2M	/evmn-vs-abeo →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000318306

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Abeona Therapeutics Inc. (ABEO) reported GAAP revenue of $5.8M (-96.8% vs. FY2024 revenue of $179.8M , and +66.3% cumulative change since FY2023) , GAAP net income of -$71.2M, operating cash flow of -$76.3M, and free cash flow of -$84.3M (-44.2% YoY). On the balance sheet, ABEO closed FY2025 with $219.6M in total assets against $7.8M in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$5.8M	-$71.2M	-$76.3M	-$84.3M	$219.6M	$7.8M
FY2024 (FY)	2024-12-31	$179.8M	$63.7M	-$56.0M	-$58.5M	$108.9M	$13.0M
FY2023 (FY)	2023-12-31	$3.5M	$54.2M	-$37.0M	-$37.0M	—	—

3. ABEO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ABEO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does ABEO compare to CAMP and AMRN in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for ABEO?

Where is ABEO trading relative to its 50-day, 200-day, and 52-week technical levels?

ABEO last traded at $4.25 (-2.30% on volume of 1,011,847 shares), positioning the stock -17.95% below its 50-day simple moving average ($5.18) and -22.45% below its 200-day simple moving average ($5.48). Across its 52-week range of $4.00 to $7.65, ABEO sits at the 6.8% percentile with a 14-day RSI of 38.7 (NEUTRAL RANGE) and an implied next-earnings move of ±9.5% ($3.85 to $4.65).

Direct Sub-Reports: ABEO RQD Cockpit ABEO 12M Forecast ABEO Earnings & Move ABEO Dividends & DRIP ABEO Insiders & 13F ABEO Whale Options ABEO Profit Sankey ABEO News & Why

ROARABLE RATING BRIEF • RQD 23/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

ABEO — Abeona Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:39:46Z

1. Roarable Rating Brief: What This Means to a Prospective Investor

ABEO carries an RQD Score of 23 out of 100, letter grade E, with the verdict label "Roarable Strong Sell — Forensic Risk / Avoid." Across the five pillars, the fundamental cash engine scores 4 of 20 (ROIC -35%; FCF yield 0%), indicating the business is not currently generating returns on capital or free cash flow. Whale 13F flow scores 3 of 20 and insider conviction scores 3 of 20, meaning the rating reads institutional accumulation, options positioning, Form 4 and Congressional PTR flows as weak. Macro regime fit scores 8 of 20 with a beta of 1.0. Forensic balance sheet scores 5 of 20, reflecting an Altman Z of 0.2, Piotroski F of 3/9, and Debt/Equity of 0.05. For a prospective investor, the implications are that the low debt load is offset by severe operating losses and a weak distress signal, so any upside would have to come from a catalyst the current cash engine does not yet support.

2. Business Model, Unit Margins & SEC Financial Trajectory

Abeona Therapeutics Inc. (ABEO) operates in the Biotechnology: Pharmaceutical Preparations industry (Health Care sector) with an equity capitalization of $248.8M, gross margin of 73.7%, operating margin of -60.0%, and return on invested capital (ROIC) of -35.0%.

Operating margin and net margin are both -60% and gross margin is 73.7%, with ROIC at -35%. Reported net income is negative in FY 2025 at -$71.2M but positive in FY 2024 at $63.7M while operating income was -$64.2M, a divergence the source does not explain. The Altman Z-Score is 0.2 and the Piotroski F-Score is 3/9, both . Debt/Equity is 0.05 and cash stood at $78.4M in FY 2025 against debt of $7.8M.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case: Debt/Equity of 0.05 and $78.4M in FY 2025 cash give the company a low-leverage balance sheet despite losses. With Fundamental Cash Engine at 4/20 (ROIC -35.0%, FCF yield —) and Institutional Whale Flow at 3/20, sustained execution supports upside toward the top of the $4.00 – $7.65 52-week range.
🐻 Primary Bear Case: ROIC of -35%, FCF yield of 0%, and an Altman Z of 0.2 signal the cash engine is not self-funding and carries distress risk. Investors must weigh current valuation against -60.0% operating margins and a 1.00 macro beta if sector demand softens.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are —

Key Question #1: What is the business model and product pipeline that produces the reported $5.8M FY 2025 revenue?
Key Question #2: What explains the positive FY 2024 net income of $63.7M against an operating loss of -$64.2M?
Key Question #3: What are the terms and outcome of the leadership-change engagement referenced in the news wire?

ABEO Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Abeona Therapeutics Inc. (ABEO) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ABEO Debate Forum (3) ↓

🟡 MARKET WIRE TradingView • 20h ago

Abeona Therapeutics Inc. Estimates – NASDAQ:ABEO

TradingView report covering Abeona Therapeutics Inc. (ABEO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE www.marketscreener.com • 23h ago

James Russell Engages and Pushes for Board and Leadership Changes at Abeona Therapeutics

www.marketscreener.com report covering Abeona Therapeutics Inc. (ABEO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo! Finance Canada • 1d ago

Mereo BioPharma Group plc (MAH0.F) Seasonal Returns Chart - Yahoo Finance

Yahoo! Finance Canada report covering Abeona Therapeutics Inc. (ABEO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Simply Wall St • 1d ago

High Growth Stocks With Strong Insider Confidence

Simply Wall St report covering Abeona Therapeutics Inc. (ABEO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE The Manila Times • 1d ago

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

The Manila Times report covering Abeona Therapeutics Inc. (ABEO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Pluang • 1d ago

OS Therapies appoints Rubenstein PR to lead glo...

Pluang report covering Abeona Therapeutics Inc. (ABEO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Pluang • 1d ago

FDA grants Fast Track status to PSV359 for trea...

Pluang report covering Abeona Therapeutics Inc. (ABEO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Pluang • 1d ago

Synthetic antibody library market to grow 12% C...

Pluang report covering Abeona Therapeutics Inc. (ABEO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ABEO Bull vs. Bear Conversation Board — What's Your Call at $4.25?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ABEO 🐻 33% BEARISH CONVICTION

SI SiliconVal_Bull Growth & Tech Investor 🐂 BULLISH 🎯 Target: $5.18 (+19.1%)

📌 Pinned Debate

Debt/Equity of 0.05 and $78.4M in FY 2025 cash give the company a low-leverage balance sheet despite losses.

Don't sleep on ABEO's setup in Health Care. Debt/Equity of 0.05 and $78.4M in FY 2025 cash give the company a low-leverage balance sheet despite losses.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (23/100) backs up the fundamental quality.

VolSurface_Trader 🐂 BULL

@ShortSeller_Dan Shorting a 3/20 institutional whale-flow stock at $4.35 is dangerous when funds are rotating into Health Care.

SH ShortSeller_Dan Forensic Short Bias 🐻 BEARISH 🎯 Target: $3.48 (-20.0%)

Spot @ $4.35

ROIC of -35%, FCF yield of 0%, and an Altman Z of 0.2 signal the cash engine is not self-funding and carries distress risk.

Fading this rally in ABEO at $4.35. ROIC of -35%, FCF yield of 0%, and an Altman Z of 0.2 signal the cash engine is not self-funding and carries distress risk.. With a beta of 1.0 and the stock sitting at $4.35 (52-wk range $4.00–$7.65), the easy multiple expansion is already priced in.